Ranolazine and Pulmonary Hypertension

Exclusion Criteria

• •1. Acute coronary syndrome or coronary revascularization within the prior 3 months.
• •2. Patients with unstable angina.
• •3. Patients with Class IV congestive heart failure.
• •4. Planned revascularization, pacemaker or defibrillator placement during the study period.
• •5. Changes in antianginal medical therapy likely to occur during the study period.
• •6. Corrected QT interval measurement \>500 ms.
• •7. Patients with pre-existing QT prolongation (including congenital long QT syndrome) or receiving other QT prolonging drugs (including Class Ia-e.g., quinidine, Class III-e.g., dofetilide, sotalol, antiarrhythmics; antipsychotics (e.g., thioridazine, ziprasidone), or known history of complex ventricular arrhythmias requiring antiarrhythmic medications or ICD implantation.
• •8. Patients with known history of hepatic dysfunction.
• •9. Current use of strong CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, saquinavir and diltizaem.
• •10. Patients with pacemakers, cochlear implants, aneurysm clips, who have worked with metal.
• •11. Patients with metallic hardware, implants, or prostheses will consult with the radiologist/cardiologist prior to the study.
• •12. Patients with severe or end stage renal disease (an estimated GFR \< 30 mL/min/1.73 m).
• •13. Women who are pregnant or lactating
• •14. Any contraindications for the use of a right heart catheter including, but not limited to:
• •* Pulmonic or tricuspid valve stenosis
• •* Prosthetic pulmonic or tricuspid valve
• •* Right atrial or ventricular masses
• •* Previous pneumonectomy
• •* Risk of severe arrhythmias, including left bundle branch block (LBBB)
• •15. Subjects unable to perform cardiopulmonary exercise testing will be excluded (i.e. extensive musculoskeletal disease)